Betty Ciesla, MS, MT(ASCP)SHCM

• Faculty, Medical Technology Program
• Morgan State University
• Baltimore, Maryland
• Assistant Professor Medical Technology Program
• Stevenson University
• Stevenson, Maryland

It is a 527 amino acid glycoprotein that is indicated to reduce the mortality associated with acute myocardial infarction erectile dysfunction 14 year old purchase cheap avanafil on line. Tenecteplase is cleared from the plasma with a half-life of 20­24 minutes erectile dysfunction neurological causes avanafil 100 mg order line, but the terminal phase halflife is 90­130 minutes (1) erectile dysfunction lipitor generic avanafil 200 mg with mastercard. Tenecteplase is a glycoprotein and cannabis causes erectile dysfunction cheap 100 mg avanafil otc, although some proteins do cross erectile dysfunction venous leak treatment buy avanafil 100 mg fast delivery, the short plasma half-life will limit the exposure of the embryo­fetus to the enzyme. Because of the nature of the indication for this agent and its very short plasma and terminal half-life, the opportunities for its use during lactation or the possible exposure of a nursing infant are minimal. Congenital malformations consisted of spinal and rib defects, deformed extremities, anophthalmia, and celosomia. Because of the potential for toxicity in a nursing infant, the safest course is not to breastfeed if this drug is administered. Tenofovir is an acyclic nucleoside analog reverse transcriptase inhibitor in the same antiviral class as abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, and zidovudine. Although normal fetal growth patterns were observed, the mean birth weight of tenofovir-exposed newborns was significantly less (about 381 vs. In addition, the crown-rump, humerus, and femur lengths were significantly reduced (2). As in the study above, fetal development was normal but body weights and crown-rump lengths were significantly less than age-matched controls. In addition, fetal insulin-like growth factor was significantly reduced, as was fetal bone porosity, but alkaline phosphatase levels were increased. Transient alterations in maternal body weights and bone-related biomarkers and elevated alkaline phosphatase were observed during treatment (3). The passage of tenofovir across the human placenta apparently has not been studied. The molecular weight (about 636 for the prodrug), and low plasma and serum protein binding, combined with the data from monkeys, suggest that the drug will cross to the human embryo­fetus. In the 6100 live births with earliest exposure in the 2nd/3rd trimesters, there were 153 infants with defects (prevalence 2. There were 288 infants with birth defects among 10,803 live births with exposure anytime during pregnancy (prevalence 2. There were 1217 outcomes exposed to tenofovir (756 in the 1st trimester and 461 in the 2nd/3rd trimesters) in combination with other antiretroviral agents. There were 26 birth defects (18 in the 1st trimester and 8 in the 2nd/3rd trimesters). In reviewing the birth defects of prospective and retrospective (pregnancies reported after the outcomes were known) registered cases, the Registry concluded that, except for isolated cases of neural tube defects with efavirenz exposure in retrospective reports, there was no other pattern of anomalies (isolated or syndromic) (4) (see Lamivudine for required statement). The same conclusion was reached in a 2003 review with the added admonishment that therapy must be continuous to prevent emergence of resistant viral strains (7). The molecular weight (about 636 for the prodrug) and low plasma (about 1%) and serum (about 7%) protein binding suggest that the drug will be excreted into human breast milk. In addition, decreased fetal weight and an increased number of supernumerary ribs were observed in rabbit offspring. The embryo­fetal toxicity in both species was attributed to maternal toxicity (1). The molecular weight (about 388 for the nonhydrated free base) is low enough that exposure of the embryo­fetus should be expected. The molecular weight (about 388 for the nonhydrated free base) is low enough that excretion into breast milk should be expected. If possible, therefore, waiting to begin treatment until after a pregnancy has been concluded would be the safest course. If terbinafine is used in pregnancy, health care professionals are encouraged to call the toll free number 800-670-6126 for information about patient enrollment in the Motherisk study. No studies evaluating the placental transfer of terbinafine in humans have been located. The molecular weight (about 328) is low enough that transfer to the embryo­fetus should be expected. In pregnant rabbits, intravaginal administration of terbinafine did not cause abortions, premature delivery, or affect fetal parameters. No specific details were given, but the milk:plasma ratio in nursing women was 7:1 (1). Because the duration of therapy is usually prolonged (6 or 12 weeks for patients with fingernail or toenail onychomycosis, respectively), the potential for serious toxicity in a nursing infant may be increased. Based on the accumulation in milk and the prolonged exposure, women taking terbinafine probably should not breastfeed. However, new data have suggested an association exists between continuous use (2 weeks) of terbutaline by any route and autism spectrum disorders. Short-term use, such as 48­72 hours to allow for corticosteroid use to improve fetal lung maturation, is probably safe, but there may be a subpopulation of mothers and fetuses at increased risk secondary to genetic predisposition. In addition, there is a report of an association between 1st trimester terbutaline exposure for asthma and cardiac defects. Because of these reports, avoiding 2-adrenergics early in gestation, except for quick relief of asthmatic symptoms with low inhaled doses, and continuous use in the 2nd/3rd trimesters appear to be warranted. During pregnancy, it is primarily used as a tocolytic agent in the late 2nd and early 3rd trimesters. Hearts were examined for cardiac damage 24 hours after the last dose and on postnatal day 30. Compared with controls, neither treatment caused an increase in cardiac anomalies. However, there was a significant decrease in the number of cardiac nuclei in female pups (2). In a surveillance study of Michigan Medicaid recipients involving 229,101 completed pregnancies conducted between 1985 and 1992, 149 newborns had been exposed to terbutaline during the 1st trimester (F. A 1983 review listed the more serious side effects of parenteral 2-sympathomimetic therapy. The more serious adverse effects are seen with continuous infusions of these drugs. Avoidance of this route of administration as well as careful selection of patients, appropriate dosing, and close monitoring of patient status may help to prevent serious maternal effects. As mentioned previously, maternal hypotension may occur, especially in the bleeding patient (11). More commonly, increases in systolic pressure and decreases in diastolic pressure occur with no reduction in mean arterial pressure and, thus, do not adversely affect the fetus (8,11,12). As with all -mimetics, terbutaline may cause transient maternal hyperglycemia followed by an increase in serum insulin levels (4,13,14). Sustained neonatal hypoglycemia may be observed if maternal effects have not terminated before delivery (13). Maternal glucose intolerance was observed at 1 hour in 19 of 30 patients receiving oral terbutaline for at least 1 week (15). Although macrosomia was not observed, the birth weights (after adjustment for gestational age) of infants from terbutaline-treated mothers had a tendency to be greater than those of babies from comparable controls (15). Tachypnea (80­100 breaths/minute) developed shortly after birth and chest radiography demonstrated mild cardiomegaly with increased pulmonary vascularity. A right ventricular biopsy obtained during cardiac catheterization showed marked myocardial fiber degeneration and focal bizarre nuclear dysmorphism. Normal electrocardiogram and echocardiogram were found on examination at 1 month of age (17). In a 1996 epidemiologic study that looked for correlations between drug exposure and major malformations, 1472 births with defects (cases) were compared with 9682 births without major or minor malformations (controls) (18). Overall, there was no significant association between 2sympathomimetics (bronchodilators) and major malformations. When the malformations were divided into 10 organ categories, an association with cardiac defects (types not specified) was significant (odds ratio 5. Therapy was stopped and 1 week later, a healthy newborn was delivered without signs of liver toxicity. The mechanism of the beneficial effects on fetal pH and heart rate are thought to be caused by relief of the ischemia produced by uterine contractions on the placental circulation. Although maternal complications may occur, few direct adverse effects, other than transient tachycardia and hypoglycemia, and the single report of myocardial necrosis, have been observed in the fetus or newborn. Compared with controls, prophylactic terbutaline in low-risk patients with twin gestations has produced significant gains in birth weights caused by longer gestational times (29). In addition, terbutaline decreases the incidence of neonatal respiratory distress syndrome in a manner similar to other -mimetics (31). Long-term evaluation of infants exposed to terbutaline in utero has been reported (32­34). A 26-year-old woman became pregnant with quadruplets after a gamete intrafallopian transfer procedure (35). She was maintained on terbutaline, except for a "24-hour rest period" every week, for 51 days. Labor progressed and a cesarean section was performed in the 28th week of gestation. Between 28 and 32 hours after birth, three of the four infants developed cardiovascular decompensation with bradycardia, metabolic acidosis, poor tissue perfusion, and decreased urine output. The conditions were resistant to standard interventions but responded to dobutamine. The authors speculated that the prolonged -sympathomimetic therapy led to downregulation of fetal -receptors (35). A study published in 2005 reported an association between continuous use of terbutaline for 2 weeks and increased concordance for autism spectrum disorders in dizygotic twins (36). The investigators concluded that genetic factors and over stimulation of 2-adrenergic receptors by terbutaline could affect developmental programs in the fetal brain leading to autism. A 2009 report examined the evidence for the use and toxicity of 2-agonists in pregnancy, particularly for terbutaline and ritodrine as tocolytic agents and albuterol for asthma (37). Based on animal and human reports, the authors concluded that there was a biological plausible basis for associating prolonged in utero exposure to 2-agonists with functional and behavioral teratogenesis, such as increased risks for autism spectrum disorders, psychiatric disorders, and poor cognitive, motor function, and school performance. The available data suggested that short-term terbutaline use (2­3 days) was not associated with these toxicities, but prolonged use (2 weeks) was associated (37). In two mothers with chronic asthma about 6­8 weeks postpartum, 5 mg 3 times daily produced mean maternal plasma levels of 1. In the second report, two mothers, both at 3 weeks postpartum and both with chronic asthma, were treated with 2. No symptoms of adrenergic stimulation were observed in the four infants and all exhibited normal development. The American Academy of Pediatrics classifies terbutaline as compatible with breastfeeding (40). Single injection of terbutaline in term labor: placental transfer and effects on maternal and fetal carbohydrate metabolism. Cardiovascular complications associated with terbutaline treatment for preterm labor. A five-year experience with terbutaline for preterm labor: low rate of severe side effects. Maternal complications of parenteral -sympathomimetic therapy for premature labor. Continuous maternal glucose measurements and fetal glucose and insulin levels after administration of terbutaline in term labor. Chronic oral terbutaline tocolytic therapy is associated with maternal glucose intolerance. Sudden, unforeseen fetal death in a woman being treated for premature labor: a case report. Myocardial necrosis in a newborn after long-term maternal subcutaneous terbutaline infusion for suppression of preterm labor. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. Maternal liver impairment associated with prolonged high-dose administration of terbutaline for premature labor. The management of preterm labor with the calcium channel-blocking agent nifedipine combined with the -mimetic terbutaline. A retrospective study on the effects of steroid administration and prolongation of the latent phase in patients with preterm premature rupture of the membranes. Antepartum administration of terbutaline and the incidence of hyaline membrane disease in preterm infants. Comparison of various -mimetics on preterm labor, survival and development of the child. Long-term subcutaneous terbutaline tocolysis: report of possible neonatal toxicity. B 2adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. This pregnancy experience, combined with the animal data, suggest that the embryo­fetal risk is low. The antifungal agent is absorbed into the systemic circulation in humans after vaginal administration. Fetal exposure to the drug is also possible by direct transfer of terconazole across the amniotic membranes after vaginal administration (1). Terconazole is a triazole antifungal agent in the same class as fluconazole, itraconazole, posaconazole, and voriconazole. In a surveillance study of Michigan Medicaid recipients involving 229,101 completed pregnancies conducted between 1985 and 1992, 1167 newborns had been exposed to terconazole during the 1st trimester (F. Specific data were available for six defect categories, including (observed/expected) 14/12 cardiovascular defects, 0/2 oral clefts, 0/0.

Notably doctor who treats erectile dysfunction 100 mg avanafil order mastercard, the presence of diabetes has been shown to increase peripheral blood monocyte count erectile dysfunction lexapro cheap 100 mg avanafil. Other drivers of inflammation and atherosclerosis relevant to diabetes are also under study erectile dysfunction pills walgreens order cheap avanafil line. Lymphocyte differentiation has important effects on atherosclerotic plaque biology impotence in diabetics purchase discount avanafil on line. Disruption of Th1 lineage reduces atherosclerosis in murine models of disease and has been generally associated with proatherosclerotic responses erectile dysfunction nursing interventions order generic avanafil. In addition, smaller subsets of T cells including T regulatory cells (Tregs) and Th17 lymphocytes exert local control on plaque inflammation and plaque expansion. Recent data demonstrate that the expansion of visceral fat is associated with a loss of local Treg cells. This highlights emerging data connecting changes in inflammatory cells and cardiometabolic issues. Although cell biologic approaches and animal models have provided key scientific insights into atherogenesis, ongoing efforts are directed toward translating these findings to human disease. The identification of stable, circulating biomarkers of inflammation has allowed investigators to test prospectively how indices of inflammation relate to atherosclerosis disease burden and clinical events, including responses to current agents and therapies under development. It is interesting to note that these drugs were in clinical use before it was realized that these receptors were also expressed in vascular and immune cells. Important, pioglitazone did not seem to have higher risk of adverse events in this study. A necessary distinction must be maintained between the biologic target and the therapeutic agent(s). The experience with pioglitazone underscores the need for those trials to be carefully thought out, given that reversal of the primary and secondary endpoints in this trial, and a longer duration, may well have had a profound effect on the diabetes therapeutic landscape. Incretins (glucagon-like peptide-1 analogs), a new therapeutic modality for diabetes, also have direct effects on the vasculature. The intricacies of this picture are evident in attempts to deconvolute the nature of the vascular biology of diabetic atherosclerosis-the factors that drive the disorder, determine outcomes, and, it is hoped, offer openings for interrupting the natural history. The challenges in understanding the molecular basis of the intersection of diabetes and atherosclerosis are legion, given overlapping issues between these two diseases: very long subclinical phases, a frequency in the population that sets up multiple confounding variables, shared mechanistic underpinnings, and cellular players such as adipocytes and macrophages with many similar characteristics. All of these issues combine with clinical experience to frame a fundamental question in this field: To what extent is diabetic atherosclerosis unique and distinct from atherosclerosis, or is it simply the same disease accelerated in the context of hyperglycemia and other factors? It is amazing that, despite intense efforts by many groups using different approaches over many years, this question remains unresolved. Clearly the issues considered here are important in diabetic atherosclerosis independent of whether they are unique to diabetes or not. Diabetic dyslipidemia is a central part of the diabetic picture, with all the key components of the arterial wall and the inflammatory system altered by interaction with the altered lipid metabolism of diabetes. Endothelial dysfunction is an early part of the disease even before diabetes or cardiovascular complications become apparent. Teno S, Uto Y, Nagashima H, et al: Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes, Diabetes Care 23:1401­1406, 2000. Augustus A, Yagyu H, Haemmerle G, et al: Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression, J Biol Chem 279:25050­25057, 2004. Assert R, Scherk G, Bumbure A, et al: Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro, Diabetologia 44:188­195, 2001. Undas A, Wiek I, Stepien E, et al: Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome, Diabetes Care 31:1590­1595, 2008. Morel O, Kessler L, Ohlmann P, et al: Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis, Atherosclerosis 212:367­376, 2010. Tsimerman G, Roguin A, Bachar A, et al: Involvement of microparticles in diabetic vascular complications, Thromb Haemost 106:310­321, 2011. Li Y, Woo V, Bose R: Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus, Am J Physiol Heart Circ Physiol 280:H1480­H1489, 2001. Randriamboavonjy V, Isaak J, Elgheznawy A, et al: Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes, Blood 120:415­423, 2012. Pedreno J, Hurt-Camejo E, Wiklund O, et al: Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of verylow-density lipoprotein particles, Metabolism 49:942­949, 2000. Anfossi G, Russo I, Trovati M: Platelet dysfunction in central obesity, Nutr Metab Cardiovasc Dis 19:440­449, 2009. Russo I, Traversa M, Bonomo K, et al: In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin, Obesity (Silver Spring) 18:788­797, 2009. De Cristofaro R, Rocca B, Vitacolonna E, et al: Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus, J Thromb Haemost 1:250­256, 2003. Aoki I, Shimoyama K, Aoki N, et al: Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes, J Am Coll Cardiol 27:560­566, 1996. Koenig W: Fibrin(ogen) in cardiovascular disease: an update, Thromb Haemost 89:601­609, 2003. Raynaud E, Pйrez-Martin A, Brun J, et al: Relationships between fibrinogen and insulin resistance, Atherosclerosis 150:365­370, 2000. Barazzoni R, Kiwanuka E, Zanetti M, et al: Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes, Diabetes 52:1851­1856, 2003. Hernбndez-Espinosa D, Ordусez A, Miсano A, et al: Hyperglycaemia impairs antithrombin secretion: possible contribution to the thrombotic risk of diabetes, Thromb Res 124:483­489, 2009. Zawadzki C, Susen S, Richard F, et al: Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins, Atherosclerosis 195:e117­e125, 2007. Yamaji K, Wang Y, Liu Y, et al: Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation, Thromb Res 115:319­325, 2005. Aso Y, Fujiwara Y, Tayama K, et al: Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor, Exp Clin Endocrinol Diabetes 109:210­216, 2001. Aso Y, Fujiwara Y, Tayama K, et al: Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes, Clin Chim Acta 301:135­145, 2000. Bayйs-Genнs A, Guindo J, Oliver A, et al: Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina, Thromb Haemost 81:865­868, 1999. Moncada S, Higgs A: the L-arginine-nitric oxide pathway, N Engl J Med 329:2002­2012, 1993. Kinlay S, Libby P, Ganz P: Endothelial function and coronary artery disease, Curr Opin Lipidol 12:383­389, 2001. Ceriello A, Mercuri F, Quagliaro L, et al: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress, Diabetologia 44:834­838, 2001. Tsuchiya K, Tanaka J, Shuiqing Y, et al: FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis, Cell Metab 15:372­381, 2012. Hernandez-Mijares A, Rocha M, Rovira-Llopis S, et al: Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia, Diabetes Care, 2013. Devaraj S, Tobias P, Jialal I: Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes, Cytokine 55:441­445, 2011. Tabas I: Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency, Arterioscler Thromb Vasc Biol 25:2255­2264, 2005. Arbustini E, Dal Bello B, Morbini P, et al: Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction, Heart 82:269­272, 1999. A frequent cause of coronary thrombosis in sudden coronary death, Circulation 93:1354­1363, 1996. Sun J, Xu Y, Dai Z, et al: Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin, Mol Cell Endocrinol 313:64­69, 2009. Christopher J, Velarde V, Zhang D, et al: Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells, Am J Physiol Heart Circ Physiol 280:H1537­H1546, 2001. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med 341:410­418, 1999. Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms, Curr Atheroscler Rep 2:327­335, 2000. Devaraj S, Glaser N, Griffen S, et al: Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes, Diabetes 55:774­779, 2006. However, T1D can also be diagnosed in adulthood; this accounts for 5% to 10% of all cases of diabetes worldwide. In the past, patients with T1D were characterized by underinsulinization and a thin body habitus. These rapid and sustained increases suggest a cause that is environmental or related to a gene-environment interaction instead of genetic shifts. Multiple ongoing studies are investigating the cause of T1D to identify targets for prevention. Moreover, the incidence rate ratio for all-cause mortality was elevated similarly for both women 2. Specific Considerations for Cardiovascular Disease in Type 1 Diabetes: Age and Comparison with Type 2 Diabetes T1D is frequently diagnosed in childhood, which includes the challenges associated with the physiologic changes of puberty. The nature of plaque in T1D is less well studied than in T2D, but the plaque may be more calcified and fibrotic and contain less lipid. More studies using techniques such as intravascular ultrasound and postmortem studies are needed. Similarly, large studies from Australia,60,61 Norway,62 and Denmark63 support improvement in HbA1c in the past decades. Refer patient to an adulthood endocrinologist once the patient is 18 years old for treatment at that time. Some data suggest that regression, or at least slowing of progression, of atherosclerosis with aggressive treatment is possible in adults. Primum non nocere: There are potential adverse events from pharmacologic treatment. Similarly, a meta-analysis found a lower relative risk for macrovascular events (0. In T1D, hypertension is related to increased risk of both microvascular77­79 and macrovascular disease. In addition to measurement of blood pressure during office visits, 24-hour ambulatory blood pressure has been used to detect reduced nocturnal dipping, which has been associated with development of microalbuminuria. Excellent reviews of the pathophysiology of lipid disorders in T1D have been published historically103 and more recently by Verges. A retrospective crosssectional analysis of 682 youth with T1D younger than 21 years revealed that 18. Additional considerations in a patient with T1D include the risk of hypoglycemia while the patient is in the fasted state, when fasting for the purpose of lipid profiling. It has been suggested that a nonfasting sample for analysis of lipids may be an effective screening tool for most people with T1D. Statins have been introduced, and the accumulation of safety and efficacy data as well as a decrease in price have led to their increased use. Similarly, in children with diabetes, an increased prevalence of obesity has been reported over the past decade. Studies have evaluated the addition of metformin to insulin to improve insulin resistance in people with T1D with mixed effects on HbA1c but some improvement in lipids. Lifestyle Modification: Smoking, Diet, and Exercise Inflammation is a fundamental factor in the cause of atherosclerosis (see also Chapter 10)136 and is implicated in the pathophysiologic process of the development of T1D (see also Chapter 3). Several studies suggest that youth with T1D are more sedentary and less fit than nondiabetic youth. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med 329(14):977­986, 1993. Cobelli C, Renard E, Kovatchev B: Artificial pancreas: past, present, future, Diabetes 60 (11):2672­2682, 2011. Thabit H, Hovorka R: Closed-loop insulin delivery in type 1 diabetes, Endocrinol Metab Clin North Am 41(1):105­117, 2012. Phillip M, Battelino T, Atlas E, et al: Nocturnal glucose control with an artificial pancreas at a diabetes camp, N Engl J Med 368(9):824­833, 2013. Incidence and trends of childhood type 1 diabetes worldwide 1990­1999, Diabet Med 23 (8):857­866, 2006. Karvonen M, Viik-Kajander M, Moltchanova E, et al: Incidence of childhood type 1 diabetes worldwide. Rewers M, Gottlieb P: Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future, Diabetes Care 32(10):1769­1782, 2009. Borch-Johnsen K: Prognosis of type 1 diabetes-mortality, accidents, and impact on insurance, Diabetes Care 22(Suppl 2):B1­B3, 1999. Pambianco G, Costacou T, Ellis D, et al: the 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience, Diabetes 55 (5):1463­1469, 2006. Standards of medical care in diabetes-2013, Diabetes Care 36(Suppl 1):S11­S66, 2013. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. Silverstein J, Klingensmith G, Copeland K, et al: Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association, Diabetes Care 28(1):186­212, 2005. Microvascular and macrovascular complications, Pediatr Diabetes 8(3):163­170, 2007. Rosenbauer J, Dost A, Karges B, et al: Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria, Diabetes Care 35(1):80­86, 2012. Stettler C, Allemann S, Jьni P, et al: Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials, Am Heart J 152(1):27­38, 2006. Conway B, Costacou T, Orchard T: Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Knerr I, Dost A, Lepler R, et al: Tracking and prediction of arterial blood pressure from childhood to young adulthood in 868 patients with type 1 diabetes: a multicenter longitudinal survey in Germany and Austria, Diabetes Care 31(4):726­727, 2008. Dost A, Klinkert C, Kapellen T, et al: Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes, Diabetes Care 31(4):720­725, 2008. Valerio G, Iafusco D, Zucchini S, et al: Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes, Diabetes Res Clin Pract 97(1):99­104, 2012.

There were six exposures in the 2nd/3rd trimesters resulting in five live births and one birth defect (12) erectile dysfunction at 25 discount 200 mg avanafil otc. A 2007 report described two siblings that developed hypocalcemic seizures shortly after birth from a mother taking topiramate throughout pregnancy (13) erectile dysfunction dr. hornsby cheap avanafil master card. The mother had developed seizures during her first pregnancy at age 20 and had been treated with valproic acid erectile dysfunction kegel exercises buy 50 mg avanafil otc. Following that pregnancy erectile dysfunction drugs new buy avanafil paypal, her anticonvulsant therapy had been changed to topiramate erectile dysfunction 16 generic avanafil 50 mg buy online, 200 mg twice daily. Seven years later she became pregnant a second time and gave birth to a normal appearing, 3153-g male infant that was formula fed. Seizures began on day 3 of life and were associated with hypocalcemia, hypomagnesemia, and hyperphosphatemia but normal parathyroid hormone concentrations. The mother subsequently delivered a normal baby girl (weight not specified) at term that was formula fed. Seizures were noted at age 7 days and were associated with the same electrolyte and hormone abnormalities as in the first case. No further seizures occurred after age 8 days, and she was discharged home on short-term courses of oral calcium and phenobarbital. Because there was no identifiable biochemical etiology for the seizures in the two infants, the seizures were attributed to hypocalcemia caused by hypoparathyroidism. It was proposed that in utero exposure to topiramate led to hypoparathyroidism and subsequent hypocalcemia via effects on protein kinase A signaling (13). In a 2012 study, 9 children of preschool age (3­7 years) exposed during pregnancy to topiramate were compared with 18 children not exposed (2). The two groups were compared on developmental measures of visual, fine and gross motor function, and behavior and cognitive functions. A dose-related interaction between topiramate and a combined oral contraceptive (ethinylestradiol 35 mcg/northethindrone 1 mg) has been reported (4,14). The concurrent use of these agents could reduce the efficacy of the contraceptive, possibly requiring a higher-dose contraceptive combination (14). Topiramate is known to induce hepatic enzymes and may increase the incidence of early hemorrhagic disease of the newborn by depleting fetal vitamin K stores. Although vitamin K1 (see Phytonadione) does not readily cross the placenta, 10 mg/day of the vitamin may be given orally to the mother in the last 4 weeks of pregnancy. This is consistent with the low molecular weight (about 339), protein binding (13%­17%), and metabolism (about 30%), and the prolonged plasma elimination half-life (21 hours). Three women who had been treated with topiramate throughout pregnancy (see above) and continued during nursing were studied (6). The minimum weight-adjusted infant doses, based on 150 mL/kg of milk per day, were about 0. Plasma concentrations of topiramate in two infants at 3 weeks of age, before and after nursing, were 1. Plasma levels in the third infant were undetectable at 2 and 4 weeks postdelivery. The elimination half-life in the infants was estimated to be about 24 hours compared with 20­30 hours among healthy adult controls. In pediatric patients (ages 2­16 years), common adverse effects (most occurred twice as often or more than those in placebo-treated patients) associated with topiramate were fatigue, somnolence, difficulty with concentration/attention, aggressive reaction, confusion, difficulty with memory, ataxia, purpura, epistaxis, infections (viral and pneumonia), and anorexia and weight decrease (4). Therefore, nursing women who are being treated with topiramate, particularly those receiving high doses, should be advised to monitor their infants for signs of toxicity and for changes in alertness, behavior, and feeding habits. Preliminary findings of the developmental effects of in utero exposure to topiramate. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplements. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. The animal reproduction data suggest risk, but the absence of human pregnancy experience prevents a more thorough assessment of the embryo­fetal risk. However, all of the indications for topotecan involve potentially fatal cancers, so if informed consent is obtained, treatment should not be withheld because of pregnancy. If an inadvertent pregnancy occurs during therapy, the woman should be advised of the unknown, but potentially severe risk for her embryo­fetus. Topotecan is indicated as secondary therapy for metastatic carcinoma of the ovary, small-cell lung cancer, and, in combination with cisplatin, recurrent or persistent carcinoma of the cervix. Binding to plasma proteins is about 35% and the terminal elimination half-life is 2­3 hours (1). The most frequent malformations involved the eye (microphthalmia, anophthalmia, rosette formation of the retina, coloboma of the retina, and ectopic orbit), brain (dilated lateral and third ventricles), skull, and vertebrae. However, topotecan is known to be genotoxic in mammalian cells and is probably a carcinogen (1). The drug also is mutagenic and clastogenic, with or without metabolic activation (1). The molecular weight (about 422 for the free base), low metabolism and plasma protein binding suggest that the drug will cross to the embryo­fetus. The molecular weight (about 422 for the free base), low metabolism and plasma protein binding (35%) suggest that the drug will be excreted into breast milk. However, if she chooses to do so, the infant should be closely monitored for the most common or serious adverse effects observed in adults. These effects include bone marrow suppression (primarily neutropenia), headache, nausea, vomiting, diarrhea or constipation, abdominal pain, alopecia, and hepatic toxicity (1). In general, exposure to diuretics in early pregnancy has not been associated with structural anomalies, but the lack of human pregnancy experience with torsemide prevents a better assessment of the embryo­fetal risk. Diuretics do not prevent or alter the course of toxemia but may decrease placental perfusion (see also Chlorothiazide) because of maternal hypovolemia characteristic of this disease. Torsemide is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. It is also indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. Doses that were 5 (rats) and 4 (rabbits) times larger caused maternal toxicity (decreased average body weight) and fetal toxicity (increased resorptions and delayed ossification) (1). No overall increase in tumor incidence was noted when torsemide was given to rats and mice throughout their lives. In addition, no mutagenic activity was noted in a variety of assays and no adverse effects were noted on the reproductive performance of male and female rats (1). The molecular weight (about 348) and moderate elimination half-life suggest that the drug will cross, but the high plasma protein binding may limit the amount available for transfer. The effect of this exposure on a nursing infant is unknown, but no adverse effects in nursing infants exposed to diuretics in milk have been reported. Of note, however, thiazide diuretics have been used to suppress lactation (see Chlorothiazide). Neonatal withdrawal is a potential complication after continuous use in the mother. The long-term effects on the neurobehavior of offspring are unknown but warrant study. Because of its low addiction potential, tramadol is not classified as a controlled substance. The drug is available only as an oral tablet in the United States but has been used both parenterally and rectally in other countries. Embryo and fetal toxicity consisted of decreased fetal weights, skeletal ossification, and increased supernumerary ribs. Transient delays in developmental or behavioral parameters were seen in rat pups (1). Tramadol has a molecular weight of about 300 and crosses the placenta to the fetus. In 40 women given 100 mg of tramadol during labor, the mean ratio of drug concentrations in the umbilical cord and maternal serum was 0. Several studies outside of the United States, some of which were reviewed in 1993 (4) and 1997 publications (3), have compared the use of tramadol with meperidine or morphine for labor analgesia (5­13). In five of these studies (5­9), the use of tramadol was associated with less neonatal respiratory depression than meperidine, but no difference was observed in four studies in comparison with meperidine or morphine (10­13). A significant increase in the incidence of neonatal respiratory depression was observed in the offspring of the meperidine group, if delivery occurred 2­4 hours after the last dose. The respiratory depressant effects of meperidine are known to be time- and dose-related, increasing markedly after 60 minutes (see Meperidine). Meperidine was associated with a significantly higher frequency of adverse effects (nausea, vomiting, fatigue, drowsiness, and dizziness) in the mothers and a significantly lower respiratory rate in the newborns. In a 1997 case report, a male infant developed withdrawal symptoms between 24 and 48 hours after birth (15). Symptoms consisted of trembling, tachypnea, tachycardia, hypertonic muscle tone, signs of tetany when touched, and a single mild convulsion. The infant was treated with diazepam and/or phenobarbital for 13 days until the symptoms had fully resolved. Four other reports, involving seven infants, have described neonatal abstinence syndrome after long-term use of tramadol (200­800 mg/day) in pregnancy (16­19). Withdrawal symptoms in the infants occurred on the second day of life and persisted for up to about 2 weeks. Results of a National Birth Defects Prevention Study (1997­2005) were published in 2011 (20). The exposure period evaluated was from 1 month before to 3 months after conception. Limiting the exposure period to the first 2 months after conception produced similar results. They concluded that the absolute risk was a modest absolute increase above the baseline risk for birth defects (20). A 2012 review of tramadol in pregnancy and lactation found no clear evidence of fetal or neonatal harm, but concluded that the drug should be avoided during conception and the 1st trimester because of lack of data during these periods (21). The recommended dose of tramadol is 50­100 mg every 4­6 hours up to a maximum of 400 mg/day. Thus, ingestion of the recommended dose may produce drug amounts in breast milk that could exceed those reported above. In a 2008 study, 75 breastfeeding mothers were taking tramadol (100 mg every 6 hours) on days 2­4 after cesarean section (22). On the study date, 49% of the subjects and 100% of the controls also took other opiate analgesics (mostly oxycodone) while 61% of the subjects and 58% of the controls also took nonsteroidal antiinflammatory agents (mostly diclofenac). For tramadol, the estimated absolute and relative infant doses were 112 mcg/kg/day and 0. Compared with controls not taking tramadol, there were no significant behavioral adverse effects (22). A 2012 review of tramadol in pregnancy and lactation concluded that the use of tramadol during early breastfeeding was unlikely to cause harm in healthy term infants (21). Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Obstetrical analgesia with tramadol-results of a prospective randomized comparative study with pethidine. Use of tramadol versus pethidine versus denaverine suppositories in labor-a contribution to noninvasive therapy of labor pain. Effectiveness and tolerance of tramadol with or without an antiemetic and pethidine in obstetric analgesia. A comparison of tramadol and pethidine analgesia on the duration of labour: a randomised clinical trial. Walking epidural with low dose bupivacaine plus tramadol on normal labour in primipara. Treatment of neonatal withdrawal with clonidine after long-term, highdose maternal use of tramadol. Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. It is indicated in the management of hypertension either alone, or in combination with other antihypertensives. Trandolapril is also indicated in the management of stable patients with heart failure or left-ventricular dysfunction after myocardial infarction. Reproduction studies have been conducted in rats, rabbits, and cynomolgus monkeys. The molecular weights (about 431 for trandolapril; about 403 for trandolaprilat) are low enough that transfer to the fetus should be expected. Because the primary means of removal of the drug is renal, the impairment of this system in the newborn prevents elimination of the drug resulting in prolonged hypotension. If oligohydramnios occurs, stopping trandolapril may resolve the problem but may not improve infant outcome because of irreversible fetal damage (6). The molecular weights (about 431 for trandolapril; about 403 for trandolaprilat) suggest that excretion into breast milk should be expected. The drug crosses the placenta to the fetus, but its reported lack of effect on plasminogen activator activity in the vascular wall (1,2) (vs. No adverse fetal effects were observed in reproductive toxicity testing in mice, rats, and rabbits (3,4). Both Schardein (5) and Shepard (6) cited a 1971 study in which doses up to 1500 mg/kg/day were given to mice and rats during organogenesis without causing adverse fetal effects. Cord serum and maternal blood samples were drawn immediately following delivery, a mean of 13 minutes after the dose of tranexamic acid. The mean drug concentrations in the cord and maternal serum were 19 mcg/mL (range <4­31 mcg/mL) and 26 mcg/mL (range 10­53 mcg/mL), respectively, a ratio of 0. Additional courses were given if bleeding continued (number of patients with repeat courses not specified).

Order 50 mg avanafil with mastercard. How much water should you drink a day?.

References

• Slieker-ten Hove MC, Pool-Goudzwaard AL, Eijkemans MJ, et al: Symptomatic pelvic organ prolapse and possible risk factors in a general population, Am J Obstet Gynecol 200(2):184, e1n7, 2009.
• Jones RA, Perez-Brayfield MR, Kirsch AJ, et al: Renal transit time with MR urography in children, Radiology 233(1):41n50, 2004.
• Brown LM, Devesa SS, Fraumeni JF Jr. Epidemiology of esophageal cancer. In: Posner MC, Vokes EE, Weichselbaum RR, eds. Cancer of the Upper Gastrointestinal Tract. Hamilton, Ontario, Canada: BC Decker; 2002:1-21.
• Jaber S, Amraoui J, Lefrant JY, Arich C, Cohendy R, Landreau L, Calvet Y, Capdevila X, Mahamat A, Eledjam JJ. Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Crit Care Med. 2006;34(9):2355-61.
• Holinger LD. Etiology of stridor in the neonate, infant and child. Ann Otol Rhinol Laryngol 1980;89:397-400.
• Hodge G, Mukaro V, Reynolds PN, et al. Role of increased CD8/CD28null T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 2011; 166: 94-102.
• Olivier A. Extratemporal resections in the surgical treatment of epilepsy. In Spencer SS, Spencer DD (eds), Surgery of Epilepsy. Boston,MA: Blackwell Scientific, 1991.
• Stephens WE, Calder A, Newton J. Source and health implications of high toxic metal concentrations in illicit tobacco products. Environ Sci Technol 2005;39(2):479-488.